PARACELSUS
MEDIZINISCHE PRIVATUNIVERSITÄT

INSTITUT FÜR EXPERIMENTELLE & KLINISCHE ZELLTHERAPIE
Vorstand: Univ.-Prof. Dr. med. Dirk STRUNK

RE: PostDoc + PhD positions at www.pmu.ac.at/celltherapy

Translational research in applied cell therapy & stem cell transplantation immunology. Platform technology development to advance stem cell-based therapies.

Salzburg, Nov.16, 2022

YOU have published experience in one of the research areas below or extended practice in technology capable to advance cell science in one of the respective topics + are interested in developing yourself in an appreciative atmosphere.

WE offer permanent positions for new members in our cooperative, friendly and inspiring team & approved salary (www.fwf.ac.at/en/research-funding/personnel-costs) in an exciting environment in the heart of Europe in Salzburg, Austria.

1. **OSTEOARTHRITIS: Nano-molecular mechanisms of cell therapy** – using 3D human cartilage differentiation models (PMC4287636) to understand cell-based regeneration (PMC5549556) & the role of cells vs. extracellular vesicles (EVs) & soluble factors (PMC9618571) in reverting inflammatory degenerative signaling cascades.

2. **HUMAN SKIN ORGANOIDS: Mechanisms of self-organization** – aiming to understand platelet-derived signaling (PMID: 26561934) during self-organization of hiPSC- and adult stem/progenitor cells towards clinical translation (PMC8344006), gene therapy development (PMC9372311) and skin cell transplantation.

3. **HUMAN iPS-CARDIOMYOCYTE TRANSPLANTATION IMMUNOLOGY** – incl. deep immunophenotyping of HLA homozygous hiPSC along 3D cardio-differentiation (PMC8192303), polychromatic FCM & CyTOF + immune assays (PMC7890556) incl. ELISPOT, CTL assays meeting data science (PMID: 36380073) from HLA typing & transplant matching to tSNE & UMAP cytometry data display (PMC8348107).

4. **EV ENGINEERING** & **EV BIOMARKERS** – pls read (PMC8994701; PMC8869293) & get inspired about biology & function of the EV corona. This topic combines nanotechnology & targeted EV therapy development / technology applicable to EV-based disease biomarkers (PMC7890556).

5. **FCM Core Facility** – if you always wanted to combine high-performance flow cytometry and sorting support as a core director with technology-driven RnD (e.g. PMID: 32542988; PMC8348107; PMC8946746), consider joining our flow core team !

OUR goal is to advance cell therapy by developing broadly applicable technology platforms for human cell therapy with a focus on human platelet lysate & cell-derived EVs in different diseases.
More details on published ideas on www.pmu.ac.at/celltherapy.

YOU are motivated to join our team – pls. send your short CV + publication record to martina.perendi@pmu.ac.at (PA of Prof. Strunk).